News Releases

Keyword Search

Nov-09-2023
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
Nov-02-2023
Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results
Oct-26-2023
Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Oct-25-2023
Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board
Oct-05-2023
Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer
Sep-07-2023
Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board
Aug-10-2023
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results
Aug-03-2023
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results
Aug-03-2023
Oncternal Therapeutics Receives FDA Study May Proceed Letter for ONCT-534, its Novel Dual-action Androgen Receptor Inhibitor, for the Treatment of Patients with Advanced Prostate Cancer
Jun-30-2023
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)